Vertex Pharmaceuticals Inc. stock rises Wednesday, still underperforms market
Shares of Vertex Pharmaceuticals Inc. VRTX advanced 1.11% to $491.64 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the S&P 500 Index SPX rising 1.12% to 5,842.63 and the Dow Jones Industrial Average DJIA rising 1.14% to 43,006.59.
Vertex Pharmaceuticals Stock: Is VRTX Outperforming the Healthcare Sector?
With a market cap of $124.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology company. The Boston, Massachusetts-based company engages in developing and commercializing therapies for treating cystic fibrosis (CF).
Bernstein Sticks to Its Hold Rating for Vertex Pharmaceuticals (VRTX)
Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price
Vertex Pharmaceuticals Leads 3 Value Stocks Offering Estimated Intrinsic Value
As U.S. markets grapple with the implications of newly imposed tariffs and economic uncertainties, investors are increasingly seeking opportunities in undervalued stocks that may offer intrinsic value amid broader market declines.
Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market
The stock's rise snapped a four-day losing streak.
TD Cowen Remains a Buy on Vertex Pharmaceuticals (VRTX)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of
Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
BioPharma Dive2h
Tris to ask for approval of dual-acting pain drug
Positive data from a pair of acute pain studies convinced the company that its drug, which works differently than existing ...
Zacks Research Issues Pessimistic Outlook for VRTX Earnings
Equities researchers at Zacks Research decreased their Q3 2026 earnings per share (EPS) estimates for shares of Vertex ...
Vertex ends gene editing research pact with Verve
Verve offered few details on the early end of a collaboration the companies inked in 2022, saying only that Vertex cited ...
Signs of hiring at Boston-area life sciences companies
Some of Massachusetts’ largest life sciences employers, as well as smaller biotechs, increased their headcount in 2024, ...
Top Biotech Stocks To Research – March 4th
AbbVie, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, and Illumina are the five Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks represent ...
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
3 Beaten-Down Biotech Stocks to Buy Before They Soar. Wall Street Is Predicting Jumps of 68% to 250%.
Fierce Biotech4h
Tris' next-gen pain drug completes trio of clinical wins, setting up push to FDA
Tris Pharma’s opioid alternative has scored a third win in a trio of clinical trials, providing the biotech with the data ...